- Advertisement -
- Advertisement -

Positive Chain of Events for Norron

- Advertisement -

Stockholm (HedgeNordic) – Swedish biopharma BioArctic AB saw its share price increase by almost 50 percent on Tuesday after Biogen announced renewed plans to seek approval for its experimental Alzheimer’s drug, aducanumab, months after discontinuing clinical studies of the same drug. As the fifth-largest shareholder in BioArctic with a 3.5 percent stake, Stockholm-based asset manager Norron AB benefited from Biogen’s announcement, which raised the probability of success of BioArctic’s experimental drug for the treatment of Alzheimer’s disease.

The Swedish asset manager’s long-only equity fund Norron Active and market-neutral equity fund Norron Alpha are both invested in BioArctic AB. The long side of Norron Alpha, a member of the Nordic Hedge Index, constitutes a replica of Norron Active’s portfolio, with the hedge fund’s beta component reduced by shorting the OMX Stockholm Benchmark (SBX).

According to fund manager Gustaf Sjögren (pictured), who manages both Norron Alpha and Norron Active, “the positive development for aducanumab is a partial confirmation of the course of action for BioArctic’s BAN2401. Despite some differences, aducanumab and BAN2401 are relatively similar molecules.”

Biogen announced plans to seek approval from U.S. Food and Drug Administration (FDA) for the drug it abandoned earlier this year. In March, Biogen halted two Phase III clinical studies after the analysis of preliminary data available at the end of December of last year suggested aducanumab was destined for failure. A larger dataset with additional data from 2019 told a different story, as patients who received higher doses of aducanumab “experienced significant benefits on measures of cognition and function such as memory, orientation, and language,” the company reported.

“What happened is quite unusual in fact,” comments Sjögren in an interview with Finwire. “Biogen had previously withdrawn its application. Before Biogen’s announcement, the estimated probability of BioArctic to succeed was at 25 percent, now it is at maybe 45-50 percent, and I think you should have a higher probability.”

At the end of September, Norron AB owned 3.05 million shares of BioArctic, sitting as the fifth-largest shareholder after Pär Gellerfors and Lars Lannfelt, the two founders of BioArctic, as well as the Third and Fourth Swedish National Pension Funds (AP3 and AP4).

Subscribe to HedgeBrev, HedgeNordic’s weekly newsletter, and never miss the latest news!

Our newsletter is sent once a week, every Friday.

Eugeniu Guzun
Eugeniu Guzun
Eugeniu Guzun serves as a data analyst responsible for maintaining and gatekeeping the Nordic Hedge Index, and as a journalist covering the Nordic hedge fund industry for HedgeNordic. Eugeniu completed his Master’s degree at the Stockholm School of Economics in 2018. Write to Eugeniu Guzun at eugene@hedgenordic.com

Latest Articles

Leveraging Opportunities in Credit Markets

Stockholm (HedgeNordic) – After several years of successful bond investing through a private investment company, Nicolai Wenckheim launched an alternative investment fund in March...

ATP’s Response to Changing Equity-Bond Correlations

Stockholm (HedgeNordic) – In 2022, the usual negative correlation between equities and bonds, essential for the construction of diversified portfolios, disappeared. This rare anomaly,...

Evolution in Hedge Fund Investing with LGT Collaboration

Stockholm (HedgeNordic) – Since Peter Ragnarsson assumed the role of Head of Alternatives at PRI Pensionsgaranti in 2015, the Swedish pension insurer has significantly...

Borea Expands Sustainability Focus with New Hire

Stockholm (HedgeNordic) – Norwegian fund boutique Borea Asset Management has expanded its management team with the hiring of Iselin Ahmer Solberg as a corporate...

Schroders Strengthens Nordic Client Team

Stockholm (HedgeNordic) – Schroders is expanding its client relationship capabilities in the Nordics with the appointment of Ludvig Löfving as a Client Director. He...

The Lynx Constellation Is Brightening Up

Stockholm (HedgeNordic) – Lynx Asset Management made headlines in late 2019 with the launch of its pure-play machine learning strategy, Constellation, as a standalone...

Allocator Interviews

Latest Articles

Man Institute Insights


Request for Proposal

- Advertisement -